Add Alzheimer’s drug lecanemab to Canada’s public drug plans, company says – Nationwide
Canada’s Drug Company is recommending that public drug plans pay for a remedy proven to gradual the development of early-stage Alzheimer’s illness if sufferers meet sure situations. Lecanemab is an antibody that targets the buildup of amyloid plaque within the mind, which is believed to be an underlying reason for the illness. Well being Canada…